New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
04:55 EDTLIFE, LIFE, LIFE, SI, SI, SI, BIOL, BIOL, BIOL, IVC, IVC, IVC, VAR, VAR, VAR, ARAY, ARAY, ARAY, CPHD, CPHD, CPHD, MASI, MASI, MASI, HRC, HRC, HRC, RHHBY, RHHBY, RHHBY, MCK, MCK, MCKWorldwide Business Research to host a conference
Field Service Medical Conference is being held in San Diego on February 19-21.
News For LIFE;RHHBY;HRC;MASI;CPHD;ARAY;VAR;IVC;BIOL;SI;MCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
05:34 EDTVARVarian Medical to make radiotherapy available for more cancer patients in Africa
Subscribe for More Information
February 25, 2015
07:18 EDTRHHBYG Corp to hold annual meeting
Subscribe for More Information
06:14 EDTRHHBYPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 24, 2015
09:06 EDTRHHBYRoche receives orphan status for treatment of pemphigus vulgaris
The FDA granted Roche's Genentech unit orphan status for rituximab, its treatment of pemphigus vulgaris.
07:05 EDTRHHBYRoche and BioMed X enter collaboration agreement to develop sensor technology
Subscribe for More Information
February 23, 2015
06:21 EDTRHHBYFacebook's shuttle drivers approve new union contract, WSJ reports
Subscribe for More Information
February 20, 2015
16:48 EDTRHHBYDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
07:23 EDTRHHBYAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
February 19, 2015
18:25 EDTRHHBYPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
09:09 EDTRHHBYLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
06:45 EDTRHHBYStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information
05:31 EDTRHHBYExelixis announces acceptance of NDA for Genentech cobimetinib
Subscribe for More Information
05:26 EDTRHHBYFDA grants Genentech cobimetinib priority review for combination use
Subscribe for More Information
February 17, 2015
16:18 EDTMASIMasimo sees FY15 EPS $1.30, consensus $1.42
Sees FY15 revenue approximately $605M, consensus $624.71M. Masimo is providing 2015 financial guidance. Due to the significant movement in foreign exchange rates over the last four months, and the assumption that those rates will continue throughout 2015, Masimo is, for the first time, providing an estimate of the impact of these foreign exchange rates on its 2015 GAAP financial guidance. Masimo expects fiscal 2015 GAAP total revenues to be approximately $605M. Masimo expects FY15 GAAP total product revenues to be $577M, including an estimated $20M revenue reduction due to unfavorable 2015 foreign exchange rate assumptions impacting product revenues compared to 2014 actual foreign exchange rates. In addition, Masimo expects approximately $28M in FY15 royalty revenues. Masimo also expects FY15 GAAP EPS of approximately $1.30, including an estimated 15c reduction due to the more unfavorable 2015 foreign exchange rate assumptions impacting revenues, cost of sales and operating expenses compared to the 2014 actual foreign exchange rates. Masimo will provide additional financial information during the conference call today. Each of the components of Masimo's guidance set forth above is an estimate only and actual performance could differ.
16:15 EDTMASIMasimo reports Q4 EPS 40c, consensus 37c
Reports Q4 revenue $161.8M, consensus $159.45M.
13:08 EDTARAYAccuray licenses validate competitiveness, says Brean Capital
Subscribe for More Information
13:04 EDTARAYAccuray says 16 hospitals in China awarded class A user licenses
Accuray announced earlier today that class A user licenses for Accuray products were awarded to 16 hospitals during February by the Chinese National Health and Family Planning Commission. TomoTherapy System licenses were received by 12 hospitals and CyberKnife System licenses were received by four hospitals. Of the 16 licenses just issued, Accuray believes that six licenses will allow orders already in backlog to be recognized as revenue in the near future and 10 licenses are expected to lead to new system orders entered into backlog in the coming months. In total, between 2013 and year to date 2015, the NHFPC has released 32 of its planned 60 licenses.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use